This single-centre , open-label , randomised , 2-period , 2-sequence , single-dose , crossover study enrolled healthy subjects aged 18 to 55 years into 1 of 4 dose groups ( 7.5 mg , 15 mg , 22.5 mg , and 30 mg ) , where they received a single dose of SC MTX and of the oral MTX tablets .